Pityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretin
| Autor: | Jason Haldas, Gauri Panse, Emily Coleman, Scott N. Gettinger, Jonathan S. Leventhal |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Leukoderma Erythroderma Case Report Dermatology Pembrolizumab pityriasis rubra pilaris Th helper T cell Acitretin 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Psoriasis immune-related adverse event medicine Adverse effect business.industry medicine.disease PD-1 programmed death 1 IL interleukin 030220 oncology & carcinogenesis PRP pityriasis rubra pilaris Pityriasis rubra pilaris pembrolizumab Sarcoidosis acitretin business irAE immune-related adverse event medicine.drug |
| Zdroj: | JAAD Case Reports |
| ISSN: | 2352-5126 |
| DOI: | 10.1016/j.jdcr.2018.06.022 |
| Popis: | Numerous cutaneous adverse effects have been associated with programmed death 1 (PD-1) inhibitors including maculopapular eruptions, pruritus, eczema, lichenoid reactions, leukoderma, psoriasis, sarcoidosis, immunobullous disorders, and Stevens-Johnson syndrome.1, 2 Here we report the first case, to our knowledge, of pityriasis rubra pilaris (PRP)-like erythroderma in the setting of anti–PD-1 therapy responsive to acitretin and topical steroids. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|